Date: 2016-02-24
Type of information: Nomination
Compound:
Company: Prothena (Ireland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 24, 2016, Prothena Corporation, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced the appointment of David B. McNinch as Chief Commercial Officer. The creation of this new senior management position with responsibility for shaping and delivering an integrated global commercial strategy reflects Prothena's continuing evolution from a development stage company to an integrated commercial organization. Prothena is currently beginning to plan for the commercialization of its lead clinical compound NEOD001 for the potential treatment of patients with AL amyloidosis.
David B. McNinch is a seasoned biotechnology executive with more than 20 years of experience of commercializing new therapies. Prior to joining Prothena, he was Senior Vice President of Commercial Operations at InterMune Pharmaceuticals, Inc. where he was responsible for building the US Commercial infrastructure and successfully launching Esbriet® (pirfenidone), until InterMune was acquired by Roche. Prior to InterMune, he was Vice President of Marketing and Managed Markets for Ipsen, Inc., and has held various senior sales and marketing positions at Affymax, Genentech, Novartis and AstraZeneca.
Financial terms:
Latest news:
